BioIntelliSense has entered into a strategic partnership with the American College of Cardiology (ACC). The arrangement specifically concerns BioIntelliSense’s BioButton and BioSticker wearables, which will be used to gather data and improve the quality of cardiac care for people in Remote Patient Monitoring (RPM) programs.
Both the BioButton and the BioSticker can be used to measure vital signs like temperature, heart rate, and respiration. The BioSticker was certified by the FDA last January, while the BioButton is a disposable variant that was released in May in response to COVID-19.
With that in mind, the ACC will offer the BioButton to guests at its Annual Scientific Session & Expo. The organization is hoping that the device will create a safer environment during the in-person event, since it can help detect symptoms of COVID-19. However, wearing the BioButton will be optional, which could limit its utility at a larger conference. ACC.21 is scheduled to run from May 15-17 in Atlanta, and will be the first major medical conference to use the BioButton.
“Together with the ACC, we can provide the cardiology community with medical-grade monitoring devices, clinically validated algorithms and RPM education that will have a profound impact on routine patient care globally,” said BioIntelliSense CEO James Mault.
“The ACC has a long history of advancing innovative solutions to transform cardiovascular care and patient outcomes,” added ACC President Athena Poppas. “We are excited by the opportunity to partner with BioIntelliSense and be on the cutting edge of an innovative technology with real-time health data and feedback.”
BioIntelliSense has also released a 5G BioHub to help consolidate and record the information gathered with the company’s various wearable devices. All of those products are compatible with BioIntelliSense’s Data-as-a-Service health monitoring platform, which was updated in March to better track the symptoms of sick patients during the pandemic.